Physician profile
Ryan B Andringa
NPI 1356132047
$892.72
in general payments reported to CMS, 2019-2025
13 companies · $893 in 2025
The $893 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $149.73 | 2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $126.98 | 2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $119.70 | 2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $99.44 | 2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $58.00 | 2025 | Dupixent |
| Electromed, INC. | $56.88 | 2025 | Smartvest |
| Viatris Specialty LLC | $55.29 | 2025 | Yupelri |
| Genzyme Corporation | $55.24 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.30 | 2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $44.08 | 2025 | |
| Jazz Pharmaceuticals INC. | $29.84 | 2025 | |
| United Therapeutics Corporation | $23.53 | 2025 | Tyvaso |
| Insmed, INC. | $19.71 | 2025 | Brinsupri, Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Andringa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.